Quality Segment
assay
≥98% (HPLC)
form
solid
solubility
DMSO: ≥28 mg/mL
originator
Johnson & Johnson
storage temp.
2-8°C
SMILES string
O=C(Nc1ccccc1)N2CCN(CC2)c3nc(ns3)-c4ccccc4
InChI
1S/C19H19N5OS/c25-18(20-16-9-5-2-6-10-16)23-11-13-24(14-12-23)19-21-17(22-26-19)15-7-3-1-4-8-15/h1-10H,11-14H2,(H,20,25)
InChI key
BHBOSTKQCZEAJM-UHFFFAOYSA-N
Biochem/physiol Actions
JNJ-1661010 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with >100-fold preferentially selective for FAAH-1 over FAAH-2. FAAH in an integral membrane enzyme within the amidase-signature family. It catalyzes the hydrolysis of several endogenous biologically active lipids and involves in a variety of physiological and pathological processes, including synaptic regulation, regulation of sleep and feeding, locomotor activity, pain and inflammation.
JNJ-1661010 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable